Isothermal Nucleic Acid Amplification Technology (INAAT) Market worth $1,651 Million by 2018

 Isothermal Nucleic Acid Amplification Technology (INAAT) Market worth $1,651                                Million by 2018    PR Newswire    DALLAS, May 16, 2014  DALLAS, May 16, 2014 /PRNewswire/ --  According to the new market research report " Isothermal Nucleic Acid Amplification Technology (INAAT) Market  by Application (Infectious Diseases, Blood Screening, Research), Products (Instruments, Reagents), End-User (Hospital, Reference Laboratories, Other) - Global Forecast to 2018 ", published by MarketsandMarkets, the global Isothermal Nucleic Acid Amplification Technology (INAAT) Market is poised to reach $1,651 Million by 2018 at a CAGR of 13.5%.  Browse 31 market data  Tables and 53 Figures spread through 215 P ages and in-depth TOC on "Isothermal Nucleic Acid Amplification Technology (INAAT) "  http://www.marketsandmarkets.com/Market-Reports/isothermal-nucleic-acid-amplification-technologies-inaat-market-839.html  Early buyers will receive 10% customization on this report.   The increasing demand for enhanced molecular testing using INAAT as well as rising incidence of infectious diseases is driving market growth over the conventional thermal polymerase chain reaction (PCR) technology.  In addition to increasing population suffering from infectious disease and cancer, promise for less expensive molecular testing using INAAT, better throughput in gene amplification, and advent of novel technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification (HDA) play pivotal role in propelling market momentum. On the other hand, inadequate advanced infrastructure and higher dependency on convention method (PCR technology) restrict market growth globally.  Amongst various applications of INAAT, prognosis and diagnosis of infectious disease allows a huge scope for market penetration of novel isothermal technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification (HDA) among others. Infectious disease application market, especially sexually transmitted disease (STD) and hepatitis A & B, is expected to witness a double digit growth rate during the forecast period. Moreover, blood screening application is also expected to be a significant revenue pocket of INAAT due to increasing practice of mandatory testing of donated blood at blood donation unit to ensure the quality of blood sample.  End-users analysis identified reference laboratory as a potential segment ensuring a rapid growth of various isothermal amplification technologies in different complex molecular testing; whereas, technology roadmap analysis expected a rapid adoption of single miniaturized devices in the global molecular diagnostics industry.  Various private investors, venture capital firms (Bill & Melinda Gates Foundation, Wellcome Trust), and public funding bodies (the National Institutes of Health and the Centers for Disease Control and Prevention) were found to be significant investors encouraging speedy penetration of advanced isothermal technologies. On the other hand, demand side analysis considered portability and affordability the major factors contributing the competitive edge to isothermal technologies as compared to convention PCR technology.  Increasing prevalence rate of infectious diseases and significant adoption of novel technologies are expected to ensure a double digit growth in emerging nations, especially in India, China, South Africa, Singapore, and Middle East. However, INAAT in developed countries is also expected to witness a steady grow in the diagnosis of various infectious diseases such as healthcare-associated infections and sexually transmitted diseases.  The key players in the Isothermal Nucleic Acid Amplification Technology (INAAT) M arket include Alere, Inc. (U.S.), Becton, Dickinson & Company (U.S.), BioHelix (U.S.), bioMerieux (France), Hologic Gene-Probe (U.S.), and QIAGEN (The Netherlands).   Browse related reports   Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR), Consumables (Genechips, Reagents for DNA Extraction & Purification, Sequencing)], Services (Sequencing & Microarray Services, and Software) - Global Forecast to 2018. http://www.marketsandmarkets.com/Market-Reports/genomics-market-613.html   Molecular Diagnostics Market - Technologies [PCR, DNA Sequencing, Microarray, Transcription Mediated Amplification, Hybridization], Applications Virology/Infectious Diseases, Cancer/ Oncology, Genetic Testing, Blood Screening, Microbiology] Global Opportunities, Competitor Analysis & Forecasts to 2017  http://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html  About MarketsandMarkets   MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.  MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology , chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, healthcare IT semiconductor and electronics, and telecommunications and IT.  We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.  Contact: Mr. Rohan North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas, TX 75252 Tel: +1-888-600-6441 Email: sales@marketsandmarkets.com  Visit MarketsandMarkets Blog http://www.marketsandmarketsblog.com/market-reports/healthcare/biotechnology Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets  
Press spacebar to pause and continue. Press esc to stop.